Patents by Inventor John Dixon Gray

John Dixon Gray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220242954
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 4, 2022
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Publication number: 20220144966
    Abstract: The present disclosure provides anti-CD38 antigen-binding proteins such as fully human anti-CD38 IgG class antibodies each having an altered amino acid sequence in their heavy chain variable region and/or light chain variable region compared to their wild type parent antibody. The present disclosure provides engineered CD38 binding proteins, particularly anti-CD38 variant antibodies, or antigen-binding portions thereof, that specifically bind CD38, and uses thereof. The disclosed anti-CD38 antigen-binding proteins and antibodies have been engineered to exhibit improved characteristics compared to the parent antibody, such as improved binding to CD38 antigen, improved binding to CD38-expressing cells, and/or higher levels of cytotoxicity. The anti-CD38 variant antibodies can cross-react (bind) with cynomolgus CD38.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 12, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Xia Cao, Heyue Zhou, John Dixon Gray, Barbara A. Swanson
  • Publication number: 20220118105
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.
    Type: Application
    Filed: November 3, 2021
    Publication date: April 21, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray
  • Patent number: 11242391
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: February 8, 2022
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Publication number: 20220025054
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Application
    Filed: July 29, 2021
    Publication date: January 27, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
  • Publication number: 20220025064
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.
    Type: Application
    Filed: October 12, 2021
    Publication date: January 27, 2022
    Inventors: John Dixon GRAY, Heyue ZHOU
  • Publication number: 20220002422
    Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 6, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
  • Publication number: 20220002415
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 6, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Patent number: 11191845
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: December 7, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray
  • Patent number: 11180568
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 23, 2021
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: John Dixon Gray, Heyue Zhou
  • Publication number: 20210330787
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: May 3, 2021
    Publication date: October 28, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Patent number: 11155628
    Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 26, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
  • Patent number: 11155623
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: October 26, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Patent number: 11111304
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: September 7, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
  • Patent number: 11027012
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 8, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Publication number: 20210163613
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Application
    Filed: January 15, 2021
    Publication date: June 3, 2021
    Inventors: HEYUE ZHOU, JOHN DIXON GRAY
  • Publication number: 20210130468
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: January 14, 2020
    Publication date: May 6, 2021
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Patent number: 10934361
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: March 2, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, John Dixon Gray
  • Patent number: 10927171
    Abstract: There is disclosed compositions and methods relating to or derived from anti-TIM3 antibodies. More specifically, there is disclosed fully human antibodies that bind TIM3, TIM3-antibody binding fragments and derivatives of such antibodies, and TIM3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 23, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou, Irina Krapf
  • Publication number: 20200399395
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 24, 2020
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, John Dixon Gray